Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire-FirstCall/--ArdeaBiosciences,Inc.(Nasdaq: RDEA...tandchiefexecutiveofficer,willpresentatthePiperJaf...ondetailsareasfollows:,PiperJaffray21stAnnualHeal...2:00p.m.EasternTime,Location:TheNewYorkPalaceHotel...r.net/ireye/,target=,_blank,title=,http://www.cor...
(Date:11/24/2009)...ew York investment bank KTA Capital,s client Neure....7 mil convertible note private placement with a U...was arranged by KTA Capital as Neuren,s exclusive ... New York (PRWEB) November 23, 2009 -- The in...C ("KTA Capital") has announced that its...
(Date:11/24/2009)...ire-FirstCall/--Sigma-AldrichCorporation(Nasdaq: S...sday,December1stat1:45PMGMTinLondon,7:45AMUS/CST.I...theInternetavailableat http://inve s tor.sig m...ntoaccessthisfile. ,, AboutSigma-Aldrich: Si...ompany.Itschemicalandbiochemicalproductsandkitsare...
(Date:11/24/2009)...PRNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX...commercializingnovelpainmanagementtherapies,announ...iveOfficer,isscheduledtopresentatthe21stAnnualPipe...009atTheNewYorkPalaceHotelinNewYork,NewYork. ,,...er,willbeavailabletorespondtoquestionsduringthepre...
Breaking Biology Technology:Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
... SBIR Grant Funding to Advance the Development of ... RNAi Drugs, CARLSBAD, Calif., Oct. 3 Isis,Pharm...that it has been,awarded a multi-year Phase 2 Smal... National Institutes of Health (NIH) for up to $1.... exploit the RNA interference (RNAi),antisense mec...
...T LAFAYETTE, Ind. - Engineers have shown how to gr...es onto the surfaces of computer chips to enhance ...ps connect to cooling devices called heat sinks. ,...n to outperform conventional "thermal interface ma... does not require elaborate clean-room environment...
...A, Calif., Oct. 2 MannKind Corporation,(Nasdaq: ...a total of,27,014,686 shares of its common stock i...ts principal stockholder, Chief Executive Officer ... groups of investors,including accounts managed by...d shares, 15,940,489 shares were sold to Mr. Mann ...
Other Biology Technology:Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics 2Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics 3Nanotube forests grown on silicon chips for future computers, electronics 2Nanotube forests grown on silicon chips for future computers, electronics 3MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 2MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 3
(Date:11/25/2009)...t State University assistant professors recently r...on (NSF) to continue research beneficial to unders...90,000. , Christopher Blackwood, assistant profe... awarded grants to support two separate research p... Litter Decomposer Communities and Functions from ...
(Date:11/24/2009)...usands of years it has been prescribed by traditio... from headaches and stomach pain to fever and flu....le University have been able to scientifically pro...a otherwise known as Brazilian mint. , Testing ... led by researcher Graciela Rocha was able to show...
(Date:11/24/2009)...science is opening new doors to understanding how ... hearing of a marine mammal or if they hear it at...X-ray scanners that NASA uses to detect flaws in t...now allowing scientists to peek inside the giant h...hree-dimensional replicas of a whale,s hearing ana...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Got a pain? -- Have a cup of Brazilian mint 2Rocket science leads to new whale discovery 2Voler Systems Reports 50 25 Growth 14626 1Voler Systems Reports 50 25 Growth 14626 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 1Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 2Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 3Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 4
...mmonwealth University Massey Cancer Center have id...ible new therapeutic target to improve the efficac...In the Nov. 1 issue of the journal Cancer Research...er cells and established a role of sphingosine kin...id mediator sphingosine-1-phosphate in the death o...
...the world is still plagued by diseases we cannot t...ast complexity of the human immune system. Danish ... help expose a complicated but crucial part of the...an lead to entirely new vaccines and treatments. ... of Health Sciences at the University of Copenhage...
...can contribute as much as vehicles to carbon emiss...hly variable. New research published in the online... quantifies these emissions and suggests fires wil...forts. , Christine Wiedinmyer of the National Cen... University of Colorado, both in Boulder, US, used...
Other Biology News:Potential new therapeutic molecular target to fight cancer 2US faces burning emissions issue 2
Mouse Anti-DNA-PKcs, phospho (Thr2609) Monoclonal Antibody, Unconjugated, Clone 10B1 from BioLegend
Rabbit Anti-Histamine H2 Receptor Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Glycogen Coprecipitant from Bioline
Biology Products: